Matthew L. Sherman
Net Worth
Last updated:
What is Matthew L. Sherman net worth?
The estimated net worth of Dr. Matthew L. Sherman is at least $4,537,251 as of 16 Feb 2024. He has earned $445,201 from insider trading and has received compensation worth at least $4,092,050 in Deciphera Pharmaceuticals, Inc..
What is the salary of Matthew L. Sherman?
Dr. Matthew L. Sherman salary is $818,410 per year as Executive Vice President & Chief Medical Officer in Deciphera Pharmaceuticals, Inc..
How old is Matthew L. Sherman?
Dr. Matthew L. Sherman is 69 years old, born in 1956.
What stocks does Matthew L. Sherman currently own?
As insider, Dr. Matthew L. Sherman owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Deciphera Pharmaceuticals, Inc. (DCPH) | Executive Vice President & Chief Medical Officer | 108,739 | $0 | $0 |
What does Deciphera Pharmaceuticals, Inc. do?
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Matthew L. Sherman insider trading
Deciphera Pharmaceuticals, Inc.
Dr. Matthew L. Sherman has made 13 insider trades between 2020-2024, according to the Form 4 filled with the SEC. Most recently he sold 2,615 units of DCPH stock worth $40,841 on 16 Feb 2024.
The largest trade he's ever made was exercising 2,942 units of DCPH stock on 2 Oct 2023. As of 16 Feb 2024 he still owns at least 108,739 units of DCPH stock.
Deciphera Pharmaceuticals key executives
Deciphera Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. Daniel L. Flynn Ph.D. (70) Executive Vice President, Chief Scientific Officer & Founder
- Dr. Matthew L. Sherman (69) Executive Vice President & Chief Medical Officer
- Dr. Stephen B. Ruddy Ph.D. (61) Senior Vice President & Chief Technical Officer
- Mr. Daniel C. Martin (50) Senior Vice President & Chief Commercial Officer
- Mr. Steven L. Hoerter (54) Pres, Chief Executive Officer & Director
- Mr. Thomas Patrick Kelly J.D. (54) Executive Vice President, Chief Financial Officer & Treasurer